Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program-Reference-Cited by-同舟云学术

Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program

Published:2021-02 Issue: Volume:232 Page:71-83
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Lottes Aaron E.,Whatley Eleni M.,Royce Sara M.,Bertges Daniel J.,Erickson Carla A.,Farb Andrew,Fox Megan L.,Jiang Jenny H.,Wang Li,Lin Asiyah Y.,Malone Misti L.,Papandreou George,Wilgus Rebecca W.,Rosenfield Kenneth,Krucoff Mitchell W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference41 articles.

1. Peripheral arterial disease, (in eng);Ouriel;Lancet,2001

2. Summary of Safety and Effectiveness Data, Zilver PTX Drug-Eluting Peripheral Stent, 2012. [Online]. Available: https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100022b.pdf August 3, 2020.

3. Summary of Safety and Effectiveness, LUTONIX® 035 Drug Coated Balloon PTA Catheter, 2014. [Online]. Available: https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130024b.pdf August 3, 2020.

4. Summary of Safety and Effectiveness, IN.PACT Admiral Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, 2014. [Online]. Available: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140010b.pdf August 3, 2020.

5. Summary of Safety and Effectiveness, Stellarex 0.035” OTW Drug-Coated Angioplasty Balloon, 2017. [Online]. Available: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160049B.pdf August 3, 2020.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA perspectives on postmarket surveillance of peripheral and aortic vascular devices;Catheterization and Cardiovascular Interventions;2024-05-19

2. Data sources and applied methods for paclitaxel safety signal discernment;Frontiers in Cardiovascular Medicine;2024-02-23

3. Alternative evidence in drug development and regulatory science;Comprehensive Precision Medicine;2024

4. Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways “LEAN” working group;Journal of Vascular Surgery;2023-11

5. Editor's Choice – RANDOMisation Screening for Drug coated or Drug Eluting Device Randomised Trials Among Patients Undergoing Endovascular FemorOPopliteal Procedures (RANDOM-STOP study);European Journal of Vascular and Endovascular Surgery;2023-09